RNS Number : 7396K
ValiRx PLC
18 December 2018





("ValiRx" or the "Company")



"Acceptance of article for publication in the 'European Journal of Drug Metabolism and Pharmacokinetics'.

"First peer-reviewed journal article accepted for publication for VAL401 clinical trial results"


London, UK., 18 December 2018: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, is pleased to announce the acceptance for publication of the first article containing results from the VAL401 clinical trial by the European Journal of Drug Metabolism and Pharmacokinetics (an Adis journal in conjunction with Springer Nature).


The peer-reviewed article will appear in the European Journal of Drug Metabolism and Pharmacokinetics early in 2019. The article details and analyses the pharmacokinetic data acquired during the VAL401, Phase II clinical trial that was concluded in Tbilisi, Georgia in 2017. VAL401 is a new formulation of the anti-psychotic drug, risperidone, enabling our oncology treatment. This analysis considers the clinical significance of the VAL401 results in comparison to previously reported data for conventional risperidone, providing a theoretical insight into the altered activity of the therapeutic.


Dr Suzy Dilly, CEO of ValiSeek, commented: "I'm delighted to be able to announce acceptance for publication of this article, which is intended to be the first in a series of results-based publications on VAL401.  Peer-reviewed publications are always interesting to complete, as the article is very much shaped and expanded by the anonymous expert reviewers, providing a respected validation of the data."


This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.


*** ENDS ***


For more information, please contact:


ValiRx plc

Tel: +44 (0) 20 3008 4416

Dr Satu Vainikka, Chief Executive

Tel: +44 (0) 20 3008 4416

Tarquin Edwards, Head of Communications.

Tel: +44 (0) 7879 458 364

Cairn Financial Advisers LLP (Nominated Adviser)

Liam Murray / Ludovico Lazzaretti

Tel: +44 (0) 20 7213 0880

Novum Securities Limited

Colin Rowbury

Tel: +44 (0) 20 7399 9400


Notes for Editors

About ValiSeek

ValiSeek Limited ("ValiSeek") is a joint venture ("JV") company between ValiRx Plc and Tangent Reprofiling Limited, part of the SEEK Group. ValiSeek was formed to progress the drug VAL401 through its remaining preclinical development and towards Phase II trials for the treatment of lung cancer and other oncology indications.


About ValiRx

ValiRx is a biotechnology oncology focused company specialising in developing novel treatments for cancer and associated biomarkers.  It aims to make a significant contribution in "precision" medicine and science, namely to engineer a breakthrough into human health and well-being, through the early detection of cancer and its therapeutic intervention.


The Company's business model focuses on out-licensing therapeutic candidates early in the development process.  By aiming for early-stage value creation, the company reduces risk considerably while increasing the potential for realising value.  The group is already in licensing discussions with major players in the oncology field.


ValiRx's two classes of drugs in development, which each have the potential for meeting hitherto unmet medical needs by existing methods, have worldwide patent filings and agreed commercial rights.   They originate or derive from World class institutions, such as Cancer Research UK and Imperial College.


Until recently, cancer treatments relied on non-specific agents, such as chemotherapy.  With the development of target-based agents, primed to attack cancer cells only, less toxic and more effective treatments are now possible.  New drugs in this group-such as those in ValiRx's pipeline-promise to greatly improve outcomes for cancer patients.


The Company listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit